登录
Reply: "Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database" [0.03%] 关于“探索性别肯定激素治疗的安全性：一项使用美国食品药品监督管理部门不良事件报告系统数据库开展的关于药物不良反应的观察性研究”的回复
Lorenzo Villa-Zapata,Ainhoa Gomez-Lumbreras Lorenzo Villa-Zapata
Incidence and Risk Factors of Hypomagnesemia in Patients With Bone Metastasis From Solid Malignancies Treated With Denosumab: A Retrospective Chart Review [0.03%] 一次回顾性病历研究中关于实体瘤骨转移患者在使用地诺单抗治疗过程中发生低镁血症的发病率和危险因素分析
Kofi N Donkor,Jane S Lee,Myrna M Hana et al. Kofi N Donkor et al.
Background: Hypomagnesemia is associated with poor clinical outcomes in cancer patients. Patients with bone metastasis from solid malignancies receiving denosumab (Dmab) to prevent skeletal-related events often receive co...
Efficacy and Safety of Testosterone Replacement in Testicular Cancer Survivors With Treatment-Influenced Hypogonadism: A Systematic Review [0.03%] 睾丸癌幸存者治疗后影响的低促性腺激素血症患者使用睾酮替代疗法的有效性和安全性：系统综述
Andrew A Fritz,Justin P Reinert Andrew A Fritz
Objective: The objective is to evaluate the efficacy and safety of testosterone supplementation in testicular cancer survivors with treatment-related hypogonadism. ...
Early Versus Late Administration of Long-Acting Insulin in Adult Diabetic Ketoacidosis [0.03%] 成人糖尿病酮症酸中毒的长效胰岛素早期与晚期治疗的效果比较研究
Michael M Do,Jacklyn A Fleury,Grant P Morgan et al. Michael M Do et al.
Background: Evidence is inconclusive if early administration of subcutaneous (SQ) long-acting insulin (LAI) in management of diabetic ketoacidosis (DKA) improves outcomes. ...
The Acute Kidney Intervention and Pharmacotherapy (AKIP) List: Standardized List of Medications That Are Renally Eliminated and Nephrotoxic in the Acutely Ill [0.03%] 急性肾干预和药物治疗（AKIP）清单：急性期肾脏排泄和具有肾毒性的标准化药物清单
Erin F Barreto,Alexis M Gaggani,Brandy N Hernandez et al. Erin F Barreto et al.
The objective of this project was to develop a standardized list of renally eliminated and potentially nephrotoxic drugs that will help inform initiatives to improve medication safety. Several available lists of medications from the publish...
Bradley Phillips,Angelina Vascimini,Chardae Whitner et al. Bradley Phillips et al.
Objective: This article reviews the published data including the pharmacology, efficacy, and safety of aprocitentan, a novel endothelin receptor antagonist developed to treat hypertension in conjunction with additional ag...
Factors Associated With Sacubitril/Valsartan Continuation and the Methods of Combining Heart Failure Medications in Patients With Heart Failure [0.03%] 心力衰竭患者沙库巴曲缬沙坦的延续治疗及联合用药方法的影响因素分析
Erika Iwasaki,Noriko Kohyama,Mayumi Inamoto et al. Erika Iwasaki et al.
Background: Sacubitril/valsartan (SV) is recommended for patients with heart failure (HF). In addition, a combination of 4 HF medications, including SV, is recommended in patients with HF with reduced ejection fraction (H...
Antibiotic De-Escalation Practices in the Intensive Care Unit: A Multicenter Observational Study [0.03%] 重症监护室抗微生物药物降级治疗实践：多中心观察性研究
Asad E Patanwala,Arwa Abu Sardaneh,Jan-Willem C Alffenaar et al. Asad E Patanwala et al.
Background: There is little known about antibiotic de-escalation (ADE) practices in the intensive care unit (ICU). Objective: The objec...
Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma [0.03%] 靶向GPRC5D的Talquetamab：复发/难治性多发性骨髓瘤双特异性抗体治疗的新前沿
Jacob Shaver,Daniel Horton,Zachery Halford Jacob Shaver
Objective: To evaluate the pharmacology, clinical efficacy, safety, dosing, administration, and clinical implications of talquetamab-tgvs, a novel bispecific antibody, in the treatment of relapsed or refractory (R/R) mult...
Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE) [0.03%] 替奈普酶与阿替普酶治疗大块肺栓塞出血结局的比较研究(TACO-PE)
Jacquelyn Crawford,Austin Roe,Jessica Brumit et al. Jacquelyn Crawford et al.
Background: Thrombolysis is recommended in the setting of massive pulmonary embolism (PE) for reperfusion of vessels but carries a serious concern for increased bleed risk. In October 2022, our institution adopted tenecte...